Trial Profile
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of INCB018424 Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2020
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Alopecia areata
- Focus Therapeutic Use
- Sponsors Incyte Corporation
- 14 Oct 2019 Primary endpoint has not been met. (Percentage of subjects achieving a Severity of Alopecia Tool score (SALT) 50 response in terminal hair (pigmented and nonpigmented) at Week 24)
- 14 Oct 2019 Results published in the Journal of the American Academy of Dermatology
- 19 Mar 2019 Status changed from active, no longer recruiting to discontinued.